MedTrace Logo

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

NCT05253131 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2026-02-11

No results posted yet for this study

Summary

A multi-institutional open-label phase 1/2 trial of selumetinib in combination with ZEN-3694 and durvalumab in refractory/unresectable sarcomas including MPNST. The phase 1 portion will be separated in two parts and will be open to all patients with refractory/relapsed sarcomas. The phase 2 portion will be for patients with refractory/unresectable NF1-associated MPNST.

Conditions

  • MPNST
  • NF1
  • Sarcoma

Interventions

COMBINATION_PRODUCT

Selumetinib + ZEN-3694 ± Durvalumab

Selumetinib and ZEN-3694 administered per protocol, with durvalumab added in later study parts.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-15
Primary Completion
2031-05-15
Completion
2032-05-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05253131 on ClinicalTrials.gov